key: cord-0911795-fhdfbcyr
authors: Zuo, Yu; Kanthi, Yogendra; Knight, Jason S.; Kim, Alfred H.J.
title: The interplay between neutrophils, complement, and microthrombi in COVID-19
date: 2021-01-13
journal: Best Pract Res Clin Rheumatol
DOI: 10.1016/j.berh.2021.101661
sha: 55c2d5d5667132a41e86c1abcbab958564a92bf1
doc_id: 911795
cord_uid: fhdfbcyr

As of the end of 2020, coronavirus disease 2019 (COVID-19) remains a global healthcare challenge with alarming death tolls. In the absence of targeted therapies, supportive care continues to be the mainstay of treatment. The hallmark of severe COVID-19 is a thromboinflammatory storm driven by innate immune responses. This manifests clinically as acute respiratory distress syndrome, and, in some patients, widespread thrombotic microangiopathy. Neutrophils and complement are key players in the innate immune system and their role in perpetuating fatal severe COVID-19 continues to receive increasing attention. Here we review the interplay between neutrophils, neutrophil extracellular traps, and complement in COVID-19 immunopathology and highlight potential therapeutic strategies to combat these pathways.

The coronavirus disease 2019 is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] . SARS-CoV-2 can present as asymptomatic infection or it may cause a wide spectrum of disease, ranging from mild upper respiratory tract infection to life-threatening sepsis with multi-organ failure [2] . Given its rapid spread, high contagiousness, and lack of specific effective treatment, this pandemic remains a global healthcare challenge [1, 3, 4] .

SARS-CoV-2 displays a complex relationship with the human immune system [5] . It has a unique ability during early infection to inhibit host type I interferon (IFN) and natural killer (NK) cell responses, thereby compromising the body's antiviral defenses and leading to high viral loads in some patients [5, 6] . As a result of initial immune evasion, the body then mounts a compensatory hyperinflammatory response to aid in viral clearance. This is characterized by persistent hyperactivation of innate immunity with overproduction of proinflammatory cytokines; hyperinfiltration of neutrophils, monocytes, and macrophages in lung parenchyma; and extensive epithelial and endothelial damage [5, 7, 8] . This fulminant inflammatory storm can lead to acute respiratory distress syndrome, and, in some patients, provokes thrombotic widespread microangiopathy resulting in multiorgan failure and death. Neutrophils and complement are key players in our innate immune system and their roles in potentiating severe COVID-19 continues to receive much attention. Here, we will review potential roles of neutrophils and complement in COVID-19 immunopathology and highlight some potential therapeutic strategies that may target these pathways.

Neutrophils are the most abundant immune cells in circulation. They act as the first responder against various infections. For decades it was assumed that phagocytosis was the primary mechanism by which neutrophils neutralized pathogens. However, in 2004 Brinkmann and colleagues described another distinct activity of neutrophils, in which neutrophils release sticky extracellular "spider webs" composed of neutrophil-derived chromatin, microbicidal proteins, and mitochondrial remnants [9] . They named this process neutrophil extracellular trap (NET) release or NETosis. NETs act to prevent the spread of infections and also use their antimicrobial peptides to kill pathogens [9, 10] . By exposing potential autoantigens, such as nucleic acids and J o u r n a l P r e -p r o o f modified proteins, NETs may also contribute to autoimmune responses in susceptible individuals [10] . In recent years it has also been revealed that NETs are prothrombotic [11] .

NETs activate platelets and the clotting cascade, and ultimately form an integral part of arterial and venous thrombi [11] [12] [13] [14] [15] .

Prior knowledge regarding NETs in viral infection. Many viruses can directly trigger NET release [16] . HIV and respiratory syncytial virus (RSV) induce NETosis via Toll-like receptormediated signaling [17, 18] . Viruses can also promote NETosis indirectly, via triggers such as IL-8, type I interferon, and activated platelets [16] . NETs contribute to antiviral immunity by immobilizing viral particles and inactivating them via the release of antimicrobial molecules such as myeloperoxidase, α-defensin, and cathelicidins [16] . While NETs help contain viral spread, they may also cause damage to the host. For example, NETs promote alveolar-capillary injury in RSV and influenza models [19] [20] [21] . High levels of NETs are observed in patients with pneumonia-associated acute respiratory distress syndrome (ARDS) [16] , where isolated neutrophils have a lower threshold for spontaneous NET release.

It was recognized early in the pandemic that many patients hospitalized with COVID-19 demonstrate neutrophilia, which predicts critical illness and in-hospital mortality [22] [23] [24] . Furthermore, autopsy reports of COVID-19 lung tissues revealed intra-alveolar and capillary neutrophil hyperinfiltration; acute capillaritis with fibrin deposition; and neutrophilic mucositis [25] [26] [27] . In April 2020, high levels of NETs in the blood of patients with severe COVID were first reported [28] . This study assessed three markers of NETs [cell-free DNA, myeloperoxidase (MPO)-DNA complexes, and citrullinated histone H3 (Cit-H3)] in sera of 50 patients hospitalized with COVID-19 as compared with 30 healthy controls [28] . All three markers were significantly elevated in COVID-19 sera, while high levels of NETs associated with the severest disease [28] . Notably, COVID-19 sera robustly trigger NET release from healthy donor neutrophils [28] . These findings were soon confirmed by independent groups. In a prospective cohort of 33 patients hospitalized with COVID-19, high levels of MPO-DNA complexes associated with severe respiratory status and worse clinical outcomes [29] . Upon convalescence, levels of MPO-DNA complexes decreased [29] . Others have also confirmed high circulating NETs among COVID-19 patients and their tendency to tracking with disease severity [30, 31] .

The first microscopic confirmation of NETs was reported in an autopsy series from New Orleans where degenerative neutrophils with strands of extracellular material that stained weakly positive for DNA were present in COVID-19 lungs [32] . Histological detection of NETs has since been made not only in the pulmonary vasculature, but also the microvasculature of the kidney and heart [30, 31, 33] . Notably, transcriptomic analysis of four COVID-19 patients' lung tissue and bronchial alveolar lavage fluid revealed marked enrichment of NET associated genes [34] .

In summary, several lines of data have supported the presence of NETs in the severest forms of COVID-19 ( Table 1) . J o u r n a l P r e -p r o o f NET induction in COVID-19. In COVID-19, NETs are likely produced in both direct and indirect fashion. NETs can be induced by incubating SARS-CoV-2 with healthy neutrophils [31] ; in this context, inhibition of either PAD4 or RNA polymerase abrogates NETosis. SARS-CoV-2 utilizes ACE2 receptor and serine protease TMPRSS2 to enter host cells [36] , and blockade of either ACE2 or serine protease activity antagonizes SARS-CoV-2-triggered NETosis [31] . Other studies have suggested that NETs are produced indirectly in COVID-19 via activated platelets.

Platelets from patients with severe COVID-19 demonstrate increased adhesion to neutrophils in vivo, while triggering NETosis from healthy neutrophils in vitro [33] . Furthermore, plateletderived molecules such as platelet factor 4 (PF4) and RANTES, which are known to trigger NETosis, are markedly elevated in COVID-19 patients [37] . Autopsy specimens have revealed co-localization of PF4 and NETs in the pulmonary vasculature [37] . Considering that severe COVID-19 is also associated with high levels of myriad cytokines and chemokines, their role as pro-NET factors should also be considered. Here, low complement C3 was found in 57% of day 1 samples in COVID-19 patients who eventually developed non-serious pneumonia [48] . This may be an underestimate of complement activation though, as C3 is an acute phase reactant [49] . Thus, normal C3 levels may also represent elevated complement activation status due to the elevated production of C3 in inflammatory states.

To counteract complement activation, viruses have developed evasion tactics. While these have yet been to be observed for coronaviruses, other viruses have well-described mechanisms (reviewed in [50] the lung of those with septal capillary injury [25] . Notably, they also found the C4d and C5b-9

colocalized with SARS-CoV-2 S protein in these organs [25] . Similarly, mannose-binding lectin (MBL), C4, C3, and C3b-9 was observed in alveolar epithelial cells and alveolar exudate in deceased patients [46] . Furthermore C5b-9 deposition was also observed in the apical brush border of tubular epithelial cells in the kidney [51] .

Additional histopathologic features with similarities to other complement-mediated diseases indicate that complement activation is a central player in severe COVID-19. Endothelial cell abnormalities, such as cellular swelling with foamy degeneration in the setting of a thrombotic microangiopathy (TMA), have been observed in numerous organs [8, [52] [53] [54] [55] [56] , consistent with C5b-9 mediated injury and a hypercoagulable state [57] . In the lungs of those with COVID-19associated acute respiratory distress syndrome (ARDS), septal microangiopathy was observed characterized by endothelial cell injury, mural fibrin deposition, and variable intraluminal thrombus formation [8, 58, 59] . Consistent with these pathologic observations, C3-deficient mice infected with SARS-CoV demonstrated less lung inflammation and injury and weight loss despite having similar viral loads compared to wild-type mice [47] .

Both proteomic [46, [60] [61] [62] [63] [64] and transcriptomic [62, 65] studies of blood and lung samples from severe COVID-19 confirm the notion that complement activation is an immune signature characteristic of severe disease. The earliest data was observed in Chinese COVID-19 patients, as elevated serum C5a was uniquely noted in those with severe (those with respiratory distress or hypoxia on room air disease compared to those with mild symptoms or healthy controls [46] .

C5a was confirmed as a potential biomarker of severe disease in a longitudinal analysis of a French cohort, and both anti-C5aR1-treated or C5aR1-knockout mice had attenuated lung injury following C5a instillation into the lungs [66] . MBL associated with plasma D-dimer concentration in a Swedish cohort of critically ill COVID-19 patients [67] . Using the Albany Medical Center (New York) cohort, plasma target metabolomics identified complement activation and its regulation as two of the top six GO (gene ontogeny) pathways unique to hospitalized COVID-19

patients requiring ICU admission compared to those on the medical floor [64] . Data from the Columbia University Irving Medical Center/New York-Presbyterian Hospital cohort confirmed J o u r n a l P r e -p r o o f these observations, as hospitalized patients with COVID-19 exhibited elevated serum levels of factor H and I along with C5, as assessed by mass spectroscopy, compared to healthy controls [60] . Using immunoassays on Norwegian cohort, elevated plasma sC5b-9, C5a, C3b/iC3b/C3c, alternative pathway C3 convertase (C3bBbP), and C4d was observed in majority of COVID-19 patients in respiratory failure and was higher compared to those were not [61] . Similar observations were made in the lungs at the transcriptomic level, as lung biopsy samples from COVID-19 patients showed a pronounced complement signature (including C3 transcripts)

following GO pathway analysis compared to healthy controls [65] . They confirmed this observation using in vitro SARS-CoV-2-infected primary bronchial epithelial cells or a type II human pneumocyte cell line (A549) with or without ACE2 overexpression, demonstrating a similar complement signature which was not observed in influenza A-or respiratory syncytial virus-infected cells [65] .

Collectively, these data provide substantial evidence that complement activation occurs in COVID-19, with emerging data that this positively correlates with disease severity.

As discussed above, NETs are webs of extracellular chromatin decorated with factors derived from neutrophil cytoplasm, granules, and mitochondria. NETs restrain invading microbes via both immobilization and killing, but when released intravascularly are an important nidus for thromboinflammation. For example, NETs activate platelets [68] , capture red blood cells [68] , and potentiate both intrinsic [13] and extrinsic pathways [69] of coagulation.

Prior knowledge regarding the interplay between NETs and complement. The communication between NETs and complement is bidirectional and, if not tightly regulated, has potential to form a self-amplifying loop. C5a recruits and then primes neutrophils for NETosis via upregulation of various immune receptors including TLRs and complement receptors such as CR1 and CR3 [70, 71] . Pathogens opsonized with C3b and iC3b may then trigger NETosis via engagement of neutrophil CR1 and CR3, respectively [72] . Furthermore, once NETs have been released into the extracellular space, complement components-and perhaps especially C1qstabilize their structure and prevent clearance by DNase I [73] .

Emphasizing the bidirectional nature of the relationship, neutrophils express Factor B, C3, and properdin, the combination of which allows for production and stabilization of the C3-convertase J o u r n a l P r e -p r o o f on the neutrophil surface [74] and also on NETs themselves [75] . At the same time, myeloperoxidase and serine proteases such as cathespin G and proteinase 3 bind to and activate properdin with the potential to further potentiate complement activation on NETs [76] .

The end result is NETs as a fertile platform for generation of anaphylatoxins C3a and C5a [73] , which can lead to further immune system activation.

NETs, complement, and thrombotic microangiopathy. Prior to COVID-19, circulating NET remnants were already known to track closely with the activity of various TMAs including thrombotic thrombocytopenic purpura [77, 78] , hemolytic uremic syndrome [79, 80] , transplantassociated TMA [78, 81] , and likely catastrophic antiphospholipid syndrome [82] . At the same time, these TMAs are also clearly complementopathies as evidenced by the utility of inhibitors of C5 cleavage as effective therapies [83] . One interesting study contrasted transplant-associated TMA with another complication of stem-cell transplant, graft versus host disease (GVHD) [84] .

While markers of endothelial damage/activation such as thrombomodulin were elevated in both situations, only transplant-associated TMA was associated with elevations in soluble C5b-9,

NET remnants including myeloperoxidase-DNA complexes, and markers of coagulation pathways such as thrombin-antithrombin complexes [84] .

The potential for cross-talk between complement and NETs has recently been evaluated in COVID-19. Specifically, Skendros and colleagues found that C3 inhibitor compstatin Cp40 disrupted tissue factor expression by COVID-19 neutrophils, while C5a receptor blockade attenuated NETosis triggered by COVID-19 platelet-rich plasma [85] . The group also found that COVID-19 NETs are decorated with especially high levels of tissue factor and through this and likely other pathways are potent activators of cultured endothelial cells [85] . Taken together, it is not difficult to see how these pathways could conspire to occlude the COVID-19 microvasculature in vivo.

As we await what will hopefully be definitive antiviral solutions to the current pandemic, antineutrophil and anti-complement therapies have potential to help mitigate the severest manifestations of COVID-19. dexamethasone. The former may modulate NETs by neutralization of cytotoxic histones [86] and by potentiation of NET clearance via DNase I [30] . At the same time, corticosteroids such as dexamethasone can also reduce NET formation in vivo [87] , most likely via modulation of the inflammatory mediators that activate neutrophils. Other agents being trialled in COVID-19 such as JAK-STAT inhibitors, anakinra (IL-1 receptor antagonist), and colchicine also have potential to reduce NET release [88] [89] [90] .

DNases. Recombinant DNase I cleaves the DNA scaffold of NETs and thereby has the potential to relieve mitigate intravascular thrombosis and airway obstruction [30] . Applying this logic, a small single-center case series has suggested that nebulized endotracheal dornase alfa (a biosynthetic form of human DNase I) reduced oxygen requirements in all treated patients [91] .

Going forward, COVIDornase (NCT04355364) and COVASE (NCT04359654) are two studies evaluating nebulized dornase alfa in prospective randomized controlled trials. While there are not (to our knowledge) any active studies for intravenous administration, one wonders if some of the product might find its way into circulation via the damaged airways of COVID-19 [92] .

Treatment by modulation of purinergic signalling with dipyridamole. Activation of surface adenosine receptors suppresses NETosis via cyclic AMP-dependent signalling [93] .

Dipyridamole is an inexpensive, FDA-approved drug with a favorable safety profile.

Dipyridamole potentiates adenosine receptor signalling by both inhibition of ectonucleoside reuptake and stabilization of intracellular cyclic AMP. Dipyridamole tempers NET release in vitro, while preventing NET-dependent thrombosis in mice [93] . In a small study, dipyridamole suppressed D-dimer levels in patients with COVID-19 [94] . Larger studies are now underway to evaluate clinical outcomes (NCT04391179, NCT04424901) [95] .

Treatment with complement inhibitors. C5 has been an early experimental target for severe COVID-19 given that eculizumab is already FDA-approved for several complementopathies.

Severe COVID-19 patients treated with C5 cleavage inhibitors (i.e. eculizimab, ravulizumab, LFG316) have resulted in success in several small case series and reports [96] [97] [98] [99] [100] [101] , and a small number of patients already on a C5 cleavage inhibitor for PNH or TMA-associated lupus nephritis failed to progress to severe COVID-19 [102] [103] [104] . A C5a inhibitor, vilobelimab (IFX-1), failed to meet the primary endpoint of improved lung function in this small (n=30) exploratory study, although two secondary outcome measures, pulmonary embolism and renal impairment, were improved in the IFX-1 treatment group [105] . It remains too early to tell whether inhibiting

A Novel Coronavirus from Patients with Pneumonia in China

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

COVID-19: Unanswered questions on immune response and pathogenesis

The pathogenesis and treatment of the

COVID-19: Complement, Coagulation, and Collateral Damage

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Neutrophil extracellular traps kill bacteria

Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review

Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis

Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state

Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils

Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1

Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death

Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones

Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Neutrophil extracellular traps in COVID-19. JCI Insight

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Vascular occlusion by neutrophil extracellular traps in COVID-19

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy

Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation

Complement and its receptors: new insights into human disease

Complement's hidden arsenal: New insights and novel functions inside the cell

The complement system in COVID-19: friend and foe?

Complement Dysregulation and Disease: Insights from Contemporary Genetics

Complement Evasion Strategies of Viruses: An Overview

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio

A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2

Acute-phase proteins and other systemic responses to inflammation

Complement and viral pathogenesis

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Endothelial cell infection and endotheliitis in COVID-19

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Thrombotic microangiopathy in a patient with COVID-19

Characterization of lactic acid bacteria isolated from vacuum-packed cooked ring sausages

Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience

C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Postmortem Examination of Patients With COVID-19

Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Large-scale Multi-omic Analysis of COVID-19 Severity. medRxiv

Complement activation in patients with COVID-19: A novel therapeutic target

Erythrocytes Reveal Complement Activation in Patients with

SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activation

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients

Extracellular DNA traps promote thrombosis

Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis

Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation

Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcgammaRIIIB and Mac-1

Influence of complement on neutrophil extracellular trap release induced by bacteria

Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease

Complement alternative pathway acts as a positive feedback amplification of neutrophil activation

Neutrophil extracellular traps can activate alternative complement pathways

Myeloperoxidase Directs Properdin-Mediated Complement Activation

Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies

Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation

Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome

Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome

Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD

Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by beta2 Integrin Mac

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Beneficial nonanticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis

Neutrophil extracellular traps regulate IL-1beta-mediated inflammation in familial Mediterranean fever

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series

Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study

Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

Eculizumab treatment for renal failure in a pediatric patient with COVID-19

Anticomplement C5 therapy with eculizumab in three cases of critical COVID-19

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

Complement C5 inhibition in patients with COVID-19 -a promising target? Haematologica

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders

Terminal complement inhibition dampens the inflammation during COVID-19

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab